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Abstract 
Background: Periodontal disease could be a risk factor for rheumatoid arthritis (RA). It is assumed that the bacterial 
strain Porphyromonas gingivalis mediates citrullination of host peptides and thereby the generation of RA‑associated 
autoantibodies in genetically predisposed individuals. For that reason non‑RA individuals who suffered from general‑
ized aggressive (GAgP, N = 51) and generalized chronic periodontitis (GChP, N = 50) were investigated regarding the 
occurrence of antibodies against citrullinated cyclic peptides (anti‑CCP) and citrullinated α‑enolase peptide‑1 (anti‑
CEP‑1) in comparison to non‑RA non‑periodontitis controls (N = 89). Furthermore, putative associations between 
infections with five periodontopathic bacteria or expression of certain human leucocyte antigens (HLA) to these 
autoantibodies were investigated.
Methods: The presence of anti‑CCP and anti‑CEP‑1 in plasma samples was conducted with enzyme linked immuno‑
sorbent assay. Subgingival plaque specimens were taken from the deepest pocket of each quadrant and pooled. For 
detection of DNA of five periodontopathic bacteria PCR with sequence specific oligonucleotides was carried out. Low 
resolution HLA typing was carried out with PCR with sequence specific primers. Differences between patients and 
controls were assessed using Chi square test with Yates correction or Fisher`s exact test if the expected number n in 
one group was <5.
Results: Two patients with GAgP (3.9 %), no patient with GChP and two controls (2.2 %, pFisher = 0.662) were posi‑
tive for anti‑CEP‑1 whereas no study participant was anti‑CCP positive. Individuals with P. gingivalis were slightly more 
often anti‑CEP‑1 positive in comparison to individuals without P. gingivalis (3.2 vs. 1.1 %, pFisher = 0.366). Carrier of HLA‑
DQB1*06 or the HLA combination DRB1*13; DRB3*; DQB1*06 were slightly more anti‑CEP‑1 positive (6.1 and 4.3 %) 
than no carriers (0.7 and 0 %, pFisher 0.053).
Conclusions: GAgP and GChP and the presence of periodontopathic bacteria are not associated with an increased 
risk for occurrence of anti‑CCP and anti‑CEP‑1 autoantibodies. The putative relationship between periodontitis and RA 
should be investigated in further studies.
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Background
The etiology and pathophysiological mechanisms of 
rheumatoid arthritis (RA) are intensively discussed (over-
view: [1–3]). It is assumed that an environmental agent 
triggers an autoimmune reaction in a genetically predis-
posed individual [4] with subsequent synovial inflamma-
tion and cartilage bone destruction [5]. This hypothesis 
is supported by the discovery of citrulline-specific auto-
immunity with generation of anti-citrullinated peptide/
protein antibodies (ACPA) in patients with RA [6, 7]. 
Citrullination is the post-translational conversion of pep-
tidylarginine to peptidylcitrulline wherein the terminal 
positively charged amino group of the arginine is cleaved. 
Citrullination could lead to changes in tertiary structure 
of the protein which render the protein more suscepti-
ble to degradation [8]. While citrullinated peptides play 
a role in a lot of physiological processes such as epithelial 
terminal differentiation, gene expression regulation and 
apoptosis, the generation of ACPAs appears to be specific 
for RA. Therefore, tests for the detection of antibodies 
against mutated citrullinated vimentin (MCV) or cyclic 
citrullinated peptides (CCP) are valuable tools especially 
for the early diagnosis of RA [9].
Citrullination is catalysed by a family of calcium-
dependent peptidylarginine deiminases (PAD). In 
humans, five types (PAD-1 to 4 and PAD-6) have been 
described [10] but only PAD-2 and PAD-4 are found in 
the synovial tissues of patients with RA and those with 
other arthritis forms [11].
RA is genetically associated with certain human leuco-
cyte antigen (HLA) class II molecules (HLA-DRB1*0101, 
-DRB1*0401 and –DRB1*0404) that contain a shared 
epitope. It is assumed that these HLA molecules may 
influence disease pathogenesis by selectively binding 
arthritogenic peptides for presentation to autoreactive 
CD4+ T cells [12]. In binding assays it was shown that 
citrullination of vimentin significantly increases peptide–
binding affinity to HLA-DRB1*0101, -DRB1*0401 and 
-DRB1*0404 in comparison to non-citrullinated vimentin 
and leads to the activation of CD4+ T cells and subse-
quently to generation of autoantibodies against citrulli-
nated peptides. In HLA alleles which were not associated 
with RA such as HLA-DRB1*0802, -DRB1*1101 and 
-DRB1*1302 such differences in binding affinity could 
not be detected [13]. These results suggest that initia-
tion of autoimmune response to citrullinated peptides is 
HLA-restricted.
The discovery that a major bacterium of periodon-
tal disease, Porphyromonas gingivalis, expresses its own 
unique PAD called PPAD [14] supported the hypoth-
eses that periodontitis and periodontopathogens may 
contribute to the etiology of RA [4]. It has been shown 
that PPAD is able to citrullinate bacterial as well as host 
peptides such as fibrinogen and α-enolase [15]. It is feasi-
ble that ACPA can be generated in the gingiva of patients 
with periodontal disease as a consequence of P. gingi-
valis-induced citrullination of bacterial or/and human 
proteins by PPAD, human PAD, or both. These ACPAs 
may be cross-reactive with synovial citrullinated peptides 
which were formed after a second inflammatory event in 
the joint [4]. Indeed, PAD-2 and PAD-4 as well as citrulli-
nated peptides were detected in human gingiva and there 
was an association between inflammation and expres-
sion of these peptides. Moreover, antibodies against CCP 
were found mostly in gingival crevicular fluid of patients 
with periodontitis in comparison to non-periodontitis 
individuals [16].
Six cross-sectional studies investigated putative asso-
ciations between periodontal disease and levels of circu-
lating ACPA. Two case–control studies demonstrated a 
slightly increased percentage of patients with aggressive 
periodontitis (AgP) who were anti-CCP positive (7.4 or 
8 %) when compared to controls (0 %) [17, 18]. No anti-
CCP antibodies were found in patients with chronic per-
iodontitis (ChP) or gingivitis [18]. However, these results 
were not statistically confirmed. In a third case–control 
study a significantly higher percentage of anti-CCP-
positivity was observed among patients with periodon-
titis (8 %) compared to healthy controls (0 %, p < 0.001). 
Additionally, the periodontitis group harboured signifi-
cantly higher levels for anti-citrullinated α-enolase pep-
tide 1 (anti-CEP-1) and anti-arginine containing enolase 
control peptide (anti-REP-1). Periodontitis patients 
who were positive for P. gingivalis in subgingival plaque 
showed a significantly increased level for anti-CCP in 
comparison to P. gingivalis-negative patients. In con-
trast, both anti-CEP-1 and anti-REP-1 levels were simi-
lar irrespective of the presence of P. gingivalis [19]. A 
fourth case–control study demonstrated in a group of 
patients with moderate to advanced periodontitis more 
individuals who were anti-CEP-1 positive when com-
pared to non-periodontitis controls (12 vs. 3 %, for age, 
gender, smoking adjusted Odds ratio: 1.65 95 % CI 0.37–
7.5, p  =  0.5) [5]. However, the number of individuals 
who were anti-CCP positive was not different (1 vs. 1 %). 
In a recently published cohort analysis among a Japanese 
healthy population slightly positive associations between 
missing teeth (adjusted OR  =  1.04 95  % CI 1.02–1.06, 
p = 0.024), the Community Periodontal Index (adjusted 
OR = 1.35 95 % CI 1.15–1.48, p = 0.0042), loss of attach-
ment (adjusted OR = 1.18 95 % CI 1.01–1.37, p = 0.037) 
to ACPA positivity was shown [20]. Finally a sixth case–
control study reported about an association between 
anti-CCP level and alveolar bone loss >20 % (p = 0.03) in 
patients with RA in comparison to patients with osteo-
arthritis [21].
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The results of the previous studies suggest that peri-
odontitis and/or the infection with P. gingivalis may be 
associated with the level of circulating ACPA. Beyond 
that the following questions were of particular inter-
est: At first, the main periodontitis forms AgP and ChP 
are different in their onset, course, and possibly in their 
underlying genetic background. Therefore, we decided to 
examine whether AgP and ChP are different in ACPA lev-
els. Secondly, we were interested in investigating whether 
apart from P. gingivalis other main periodontopathic 
bacteria were associated to ACPA. Thirdly, because gen-
eration of ACPA is HLA-restricted, it is important to 
investigate whether certain RA-related HLA-alleles are 
associated to ACPA in patients with periodontitis.
Therefore the first aim of this study was to investi-
gate the level of ACPA in patients with generalized AgP 
(GAgP) and generalized ChP (GChP) in comparison to 
controls without periodontitis. Secondly, we examined 
whether the formation of ACPA was also associated with 
the presence of Aggregatibacter actinomycetemcomi-
tans, Prevotella intermedia, Tannerella forsythia, and 
Treponema denticola in subgingival plaque specimens. 
Finally we aimed at investigating whether ACPA forma-
tion was associated with the individual expression of RA-
related HLA alleles. For the analysis of ACPA, we include 
anti-CCP and anti-CEP-1. Anti-CCP antibodies are 
highly specific for RA (92–98 % vs. asymptomatic blood 
donors 0.5  %) and have important relevance for early 
diagnosis of the disease [22]. Citrullination of α-enolase 
was found to be related to P. gingivalis strains [15]. Anti-
CEP-1 antibodies were observed in 37–62 % of patients 
with RA (healthy controls 2 %) [23].
Methods
Study population and clinical investigations
The study was approved by the local ethics committee 
and was carried out in accordance with the ethical guide-
lines of the “Declaration of Helsinki” 1975 and its amend-
ment in “Tokyo and Venice”. The study was performed at 
the Department of Operative Dentistry and Periodontol-
ogy of the Martin-Luther University Halle-Wittenberg. 
The patients and controls were recruited from June 1996 
to May 2014 as previously published [24]. Therefore, the 
inclusion and exclusion criteria are only briefly described.
Overall, 51 patients with GAgP, 50 patients with GChP 
and 89 individuals without periodontitis were included. 
All individuals were unrelated Germans of Caucasian 
descent. They had no known medical or general health 
conditions that might profoundly contribute to develop-
ment of periodontitis. For instance, patients with RA, 
diabetes mellitus, Morbus Crohn, coronary heart disease, 
patients who took regularly anti-inflammatory drugs 
or developed gingival overgrowth due to specific drugs 
such as anti-epileptics, calcium-channel blockers, cyclo-
sporine and pregnant women were not included. Moreo-
ver, the use of antibiotics or subgingival scaling and root 
planing 6  months before the beginning of clinical and 
microbial examination led to exclusion.
The patients were assessed as previously described [24] 
in accordance with the new classification system of peri-
odontal diseases [25].
Patients with GChP were selected if they showed a 
clinical attachment loss (AL) ≥4 mm in at least 30 % of 
the teeth. The amount of destruction of the periodontal 
tissues was commensurate with the presence of micro-
bial plaque including subgingival calculus and other local 
predisposing factors. In the radiographs an even horizon-
tal bone reduction was frequently visible. Angular bony 
defects were rare.
Patients with GAgP were included only in case of evi-
dence (dental history and/or radiographs) that the age of 
onset was <35 years. At the time of the clinical diagnosis 
they had an AL ≥4 mm of at least 30 % of the teeth. In 
order to exclude a localized aggressive periodontitis at 
least three teeth had to be affected which were not first 
molars or incisors. Conversely to GChP, the severity of 
destruction of periodontal tissues was inconsistent with 
the amount of microbial deposits. In the radiographs 
angular bony defects were often visible.
Periodontitis-free individuals were included only in 
case they were not younger than 30  years and did not 
have any clinical attachment loss, i.e., PD values ≤3.5 mm 
and no gingival recession due to periodontitis. Individu-
als with vestibular AL values of >3.5 mm caused by trau-
matic tooth brushing or former orthodontic therapy were 
not considered as cases of periodontitis. AL due to over-
hanging subgingival restorations or endodontic lesions 
on single teeth did not lead to exclusion, if all other teeth 
had no signs of a periodontitis. Moreover, pseudo pock-
ets over the cemento–enamel junction with a pocket 
depth of >3.5 mm on the last molars were not considered 
as periodontitis case.
During anamnesis the periodontitis patients were 
asked about the onset and course of the diseases. Patients 
with GAgP often reported fast progression of the disease 
and episodes of acute gingivitis, abscess formation, tooth 
loosening or dental loss caused by tooth loosening, and 
many unsuccessful attempts to heal the disease. Addi-
tionally, all participants were questioned regarding their 
smoking status. A person who smoked at least one ciga-
rette per day was considered a current smoker. A smoker 
who had no smoked for at least 1 year was defined as past 
smoker. The clinical assessment included the determina-
tion of the approximal plaque index (API %) [26], the per-
centage of teeth with bleeding on probing (BOP %), PD 
(mm) as a distance between the gingival margin and the 
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bottom of the pocket, and clinical AL (mm) as a distance 
between the cemento-enamel junction and the bottom of 
the pocket.
For each tooth both the maximal values for PD and AL 
were derived by measuring six sites around each tooth. 
In order to determine the extent of periodontitis in one 
person, the percentage of teeth with AL of more than 
6 mm was recorded. The demographic and clinical data 
are given in Table 1.
Molecular assessment of periodontopathic bacteria
After removal of supragingival plaque and relative drying, 
microbial samples were taken from the deepest pocket 
of each quadrant by insertion of a sterile paper point for 
20 s. All bacterial plaque samples of each individual were 
pooled in one tube.
A molecular biological test (Micro-Ident test, Hain 
Lifescience, Nehren, Germany) was used for identifica-
tion of the five periodontogenic bacterial species. The 
whole procedure was divided into three steps, i.e. DNA 
isolation, multiplex amplification with biotinylated prim-
ers, and reverse hybridization.
The preparation of bacterial DNA was carried out 
using a commercial DNA kit (QIAamp DNA Mini Kit; 
Qiagen, Hilden, Germany) according to the producer’s 
manual. For specific amplification of bacterial DNA 
17.5  µl Primer-Nucleotide-Mix, 2.5  µl 10× polymerase 
incubation buffer, 1  µl MgCl2 solution, 2.5  µl test DNA 
and 1.65  µl water were required. PCR was performed 
(5 min 95 °C; 10 cycles: 30 s 95 °C, 2 min 58 °C, 40 s 70 °C; 
20 cycles: 25 s 95 °C, 40 s 53 °C, 40 s 70 °C; 8 min 70 °C) 
in a personal cycler (PE 9600, Perkin Elmer, Weiterstadt, 
Germany). The hybridization includes the following 
steps: chemical denaturation of the amplification prod-
ucts, hybridization of the single-stranded, biotin-labelled 
amplicons to membrane-bound probes, stringent wash-
ing, addition of a strepavidin/alkaline phosphatase con-
jugate, and an alkaline phosphatase-mediated staining 
reaction. The presence of the bacterial DNA was deter-
mined on a strip visually by means of coloured bands. In 
order to validate the correct performance of the test and 
the proper functioning of reagents, each strip included 
two control zones: Firstly, a conjugate control zone to 
check the binding of the conjugate on the strip and a cor-
rect chromogenic reaction, secondly an amplification 
control zone to check whether a control amplicon gener-
ated during amplification bound on the strip. The detec-
tion limit for all bacteria was 104 genome equivalents 
with the exception of A. actinomycetemcomitans with 103 
genome equivalents.
Determination of anti‑CCP and anti‑CEP‑1
Plasma anti-CCP and anti-CEP-1 concentrations were 
determined via an enzyme linked immunsorbent assay 
(ELISA) (Euroimmun, Lübeck, Germany). Microtiter 
plates coated with either CCP or CEP-1 were incubated 
Table 1 Clinical characteristics of the patient groups in comparison to the control group (no periodontitis)
AL clinical attachment loss.
* p ≤ 0.05 in comparison with the control group.
Generalized aggressive 
periodontitis (N = 51)





 Age median (25th/75th percentiles) 42.0 (36.0/49.0)* 48.0 (43.0/56.3)* 44.0 (39.0/56.0)
 Females, n (%) 29 (56,.9) 31 (62.0) 45 (50.6)
 Current smoker, n (%) 17 (33.3) 13 (27.1) 19 (21.3)
 Current and past smokers, n (%) 26 (51.0) 23 (47.9) 33 (37.1)
 Approximal plaque index % 57.0 (32.0/71.0) 56.0 (36.8/87.0) 43.0 (31.4/61.0)
 Bleeding on probing (%) median (25th/75th percentiles) 88.0 (75.0/100.0)* 79.5 (61.3/93.3)* 44.8 (30.0/63.0)
 Probing depth (mm) median (25th/75th percentiles) 5.3 (4.6/6.6)* 4.9 (4.2/6.1)* 2.6 (2.2/2.8)
 Clinical attachment loss (mm) median (25th/75th percentiles) 6.2 (5.7/7.3)* 5.8 (4.7/6.8)* 2.9 (2.6/6.3)
 Teeth with AL >6 mm (%) median (25th/75th percentiles) 46.4 (34.5/60.7)* 32.3 (14.1/57.4)* 0
 Missing teeth median (25th/75th percentiles) 2.0 (0/4.0) 3.0 (1.0/6.0) 2.0 (0/4.0)
Individual occurrence of periodontal bacteria in subgingival pockets
 A. actinomycetemcomitans, n (%) 18 (35.3)* 20 (40.8)* 15 (17.0)
 P. gingivalis, n (%) 37 (72.5)* 37 (75.5)* 19 (21.6)
 P. intermedia, n (%) 28 (54.9)* 30 (61.2)* 27 (30.7)
 T. forsythia, n (%) 43 (84.3) 47 (95.9)* 60 (68.2)
 T. denticola, n (%) 43 (84.3)* 47 (95.9)* 55 (62.5)
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for 60  min with plasma samples (1:101 dilution) before 
washing. As detection antibody an anti-human IgG per-
oxidase-conjugate was applied for 30  min, for visualisa-
tion tetramethylbenzidine for 30 min. Optical density 
(OD) was determined at 450  nm (reference wavelength 
620 nm). All procedures were carried out at room tem-
perature. Antibody concentrations were determined in 
duplicates and mean values were calculated. The cut-off 
values were 5 RE/ml for anti-CCP and 20 RE/ml for anti-
CEP-1. If a study participant had an antibody concentra-
tion about the cut-off he was considered as anti-CEP-1 or 
anti-CCP positive.
Genomic HLA typing
Preparation of genomic DNA from fresh human venous 
EDTA-blood was carried out by using a salting out pro-
cedure to extract DNA from human nucleated cells 
[27]. After lysis of erythrocytes by Red Cell Lysis Buffer 
(RCLB) and protein digestion by proteinase K, DNA was 
extracted by precipitation of proteins using a saturating 
salt solution. Final purification of the DNA was effected 
by ethanol precipitation.
All patients were DNA typed by standard PCR (2 min 
94 °C; 10 cycles: 10 s 94 °C, 1 min 65 °C; 20 cycles: 10 s 
94 °C, 50 s 65 °C, 30 s 94 °C) with sequence specific prim-
ers (SSP) and by use of a thermocycler (PE 9600, Per-
kin Elmer, Weiterstadt, Germany) for HLA-A, -B, -C 
(Deutsche Dynal AG, Hamburg, and Cyclerplate Sys-
tem, Protrans, Hockenheim, Germany) and HLA-DRB1, 
-DRB3/4/5, -DQB1 allele groups (Histotype-DR,-DQ, 
BAG, Lich and HLA-Ready Gene DRDQLow Inno-Train, 
Kronberg, Germany) in low resolution technique accord-
ing to the protocol provided by the manufacturer. After 
separation of the PCR products by electrophoresis in 
agarose gel containing ethidium bromide, the genotype-
specific pattern became visible on a cross linker (Gel 
Print 1000i+, MWG Biotech, Ebersberg, Germany) by 
ultraviolet stimulation.
Statistical analysis
Statistical analyses were carried out using commercially 
(SPSS v.19.0 package, IBM, Chicago, IL, USA) avail-
able software. Values of p ≤0.05 were considered to be 
significant.
Metric demographic and clinical data were checked 
for normal distribution using the Kolmogorov–Smirnov 
test and the Shapiro–Wilk test. As all metric values were 
not normally distributed, they were plotted as median 
and 25th/75th percentiles. For statistical evaluation, the 
Mann–Whitney U test was used.
Categorical variables such as number of patients who 
were positive for anti-CCP or anti-CEP-1 antibodies 
in dependence on periodontal diagnosis or in depend-
ence on the occurrence of certain bacteria in subgingival 
plaque specimens were compared with Chi square test. 
The P values were corrected with Yates continuity cor-
rection. If the expected number n in one group was <5, 
Fisher’s exact test (pF) was used.
Study participants who were positive for anti-CCP or 
anti-CEP-1 antibodies were investigated regarding the 
occurrence of common HLA markers or HLA combina-
tions. If such common HLA associations were found, we 
compared these results with study participants who were 
anti-CCP or anti-CEP-1 negative. This comparison was 
also carried out with Chi square test. The p values were 
corrected with Fisher`s exact test (pF).
Results
Demographic and clinical variables
At the time of examination, patients with GAgP were sig-
nificantly younger and patients with GChP significantly 
older than individuals who had no periodontitis. More-
over, with the exception of the API and the number of 
missing teeth, all clinical periodontal parameters, such 
as BOP, PD, AL and percentage of teeth with AL >6 mm, 
were significantly increased in the two periodontitis 
groups as compared to the control group. Apart from T. 
forsythia in patients with GAgP all investigated periodon-
tal bacteria were more often found in patients with GAgP 
and GChP in comparison to controls (Table 1).
Anti‑CCP and Anti‑CEP‑1 plasma level in dependence 
on the periodontal diagnosis
The number of individuals presenting with anti-CCP and 
anti-CEP-1 antibodies as well as the median plasma lev-
els should be compared between patients with GAgP and 
non-periodontitis controls and between GChP and con-
trols, respectively.
Neither in the patient groups nor in the control group 
anti-CCP positive individuals were found. Because the 
results for anti-CCP plasma concentrations below the 
cut-off are uncertain, we did not compare anti-CCP 
median levels in dependence on periodontal diagnosis, 
infection with certain bacteria or individual expression of 
HLA alleles.
For anti-CEP-1, two patients with GAgP (3.9  %) and 
two control individuals (2.2  %) were found positive 
(pF = 0.622), while none of the GChP patients had anti-
CEP-1 antibodies (pF = 0.536).
The medians of anti-CEP-1 levels between the patient 
groups (GAgP = 1.23 UE/ml, GChP = 1.21 UE/ml) and 
the controls without periodontitis (1.39 UE/ml) were not 
significantly different (Fig. 1).
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Anti‑CEP‑1 plasma level in dependence on the detection 
of periodontal bacteria in the subgingival plaque
In the entire study group individuals who were infected 
with P. gingivalis were slightly more often anti-CEP-1 
positive (3.2 vs. 1.1 %, pF = 0.303) than study participants 
without P. gingivalis infection. In contrast, infection with 
A. actinomycetemcomitans (1.9 vs. 2.2  %), P. intermedia 
(1.2 vs. 2.9 %), T. forsythia (2.0 vs. 2.6 %) or T. denticola 
(2.1 vs. 2.3  %) was associated with a slightly lower per-
centage of anti-CEP-1 positive individuals. These dif-
ferences were not significant. Additionally, there were 
no significant differences in the anti-CEP-1 medians in 
dependence on infection with certain periodontopathic 
bacteria (Fig. 2a–e).
Anti‑CEP‑1 plasma level in dependence on the expression 
of certain HLA alleles
Study participants who were carrier of the HLA marker 
DQB1*06 or the combination HLA-DRB1*13; DRB3*; 
DQB1*06 were slightly more often anti-CEP-1 positive 
than individuals who did not express these HLA alleles 
(4.43 vs. 0 %, pF = 0.053 and 6.1 vs. 0.7 %, pF = 0.053). 
The medians of the anti-CEP-1 plasma levels were not 
significantly different (Fig. 3a, b). There was no significant 
association between anti-CEP-1 levels and RA-related 
HLA alleles such as HLA-DRB1*01 or HLA-DRB1*04.
Anti‑CEP‑1 plasma level in dependence on the smoking 
status
Study participants who smoked (current and past 
smoker) were slightly more often anti-CEP-1 
positive than individuals who never smoked (3.7 vs. 
0.9 %, pF = 0.221). Moreover there was no significant dif-
ference in anti-CEP-1 plasma levels regarding the smok-
ing status (1.32 vs. 1.31 RE/ml, p = 0.948).
Discussion
Numerous studies reported that periodontitis could be 
a putative risk factor for RA. This relationship could be 
caused by (1) the coexistence of common risk factors for 
the two diseases such as age, smoking, and gender, (2) a 
common immunoregulatory imbalance [28], (3) underly-
ing shared genetic risk factors [29], and (4) the possibil-
ity that periodontopathic bacteria could contribute to the 
etiology of rheumatic diseases [30]. The latter aspect was 
emphasized by several studies: For instance, antibodies 
against periodontopathogens were detected significantly 
more often in both serum [31–34] and synovial fluid [35] 
in patients with RA than in controls. Moreover, patients 
with periodontitis who were rheumatoid factor (RF)-
seropositive presented elevated immunoglobulin (Ig)-M 
and IgG profiles against certain periodontophathic spe-
cies versus RF-negative periodontitis subjects [36]. DNA 
of periodontopathic bacteria was detected in synovial 
fluid and the detection frequency of P. gingivalis was 
higher in patients with RA than in controls [37–39]. In 
in  vitro experiments, P. gingivalis was found to invade 
primary chondrocytes which were isolated from knee 
joints and to induce cellular effects such as increasing cell 
apoptosis [40, 41]. These latter results might indicate that 
articular tissues could be damaged directly by living peri-
odontal bacteria.
Recent studies suggest that periodontitis or the infec-
tion with P. gingivalis could trigger the break of immu-
notolerance to citrullinated peptides and in consequence 
the development of RA. In line with this hypothesis peri-
odontitis was found associated with increased ACPA lev-
els in gingival crevicular fluid [16] and peripheral blood 
stream [5, 17–19]. The aims of the present study were 
to investigate whether the generation of ACPA is dif-
ferent in patients with GAgP and GChP in comparison 
to non-periodontitis controls, whether other key peri-
odontopathic bacteria than P. gingivalis are associated 
to increased ACPA levels at all and whether RA-related 
HLA alleles are associated with the amount of circulating 
ACPAs.
According to anamnesis no study participant suffered 
from RA because RA is highly associated to ACPA posi-
tivity and the aim was to investigate a putative associa-
tion between periodontitis and the presence of ACPA. 
Of course it is not impossible that a patient with peri-
odontitis or a control individual had a not yet discovered 



















Fig. 1 Boxplots of anti‑CEP‑1 plasma levels in dependence on peri‑
odontal diagnosis. Two patients with aggressive periodontitis (GAgP) 
and two controls were anti‑CEP‑1 positive. The medians of anti‑CEP‑1 
plasma levels between the groups were compared using Mann–
Whitney U test.
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Fig. 2 a–e Boxplots of anti‑CEP‑1 plasma levels in dependence on infection with the periodontal bacteria A. actinomycetemcomitans (a), P. gingivalis 
(b), P. intermedia (c), T. forsythia (d) and T. denticola (e). The medians of anti‑CEP‑1 plasma levels between the groups were compared using Mann–
Whitney U test.
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this risk is very low and only marginally affects the study 
results.
Among patients with GAgP we revealed slightly more 
patients who were positive for anti-CEP-1 when compared 
to controls without periodontitis (3.9 vs. 2.2  %) whereas 
in the GChP group no patient was anti-CEP-1 positive. 
Against that none of the study participants was anti-CCP 
positive. Among all study participants P. gingivalis posi-
tive patients had only slightly higher anti-CEP-1 levels (3.2 
vs. 1.1 %). An infection with A. actinomycetemcomitans, P. 
intermedia, T. forsythia, and T. denticola was not associated 
with anti-CEP-1 antibodies. Individuals who were carri-
ers of HLA-DQB1*06 or HLA-DRB1*13;DRB3*;DQB1*06 
were slightly more often anti-CEP-1 positive (4.4 vs. 0  % 
and 6.1 vs. 0.7 %). An association to RA-associated HLA 
alleles could not be demonstrated.
Since our results were statistically not significant we 
cannot confirm the findings of three previous studies 
where significant associations of periodontitis or detec-
tion of P. gingivalis to anti-CCP and/or anti-CEP-1 lev-
els were shown [5, 19, 20]. The percentage of anti-CEP-1 
positive individuals among our patients with GAgP 
(3.2  %) was only slightly elevated in comparison to the 
normal population (2  %) [4]. Since no study individual 
was anti-CCP positive, our data are even below the nor-
mal distribution (asymptomatic blood donors, 0.5  % 
[21]). In consequence the results of the present study did 
not support the hypothesis of periodontitis-induced RA-
associated ACPA which could predispose individuals for 
the development of RA.
The differences between the results revealed in our 
study in comparison to previous papers in which signifi-
cant findings were presented can be explained as follows: 
First of all, ACPAs are in general highly specific for RA 
and occurred only rarely in non-RA groups. Although 
significant, the previously published differences between 
patients with periodontitis and non-periodontitis indi-
viduals were rather low. For instance, Lappin et  al. [19] 
investigated 39 patients with periodontitis and 36 con-
trols and only 3 patients with periodontitis (7.7  %) but 
no control individuals were anti-CCP positive. A second 
reason could be the different definition of patient groups. 
De Pablo et al. [5] examined patients with moderate and 
advanced periodontitis and like in Lappin et  al. no dis-
tinction between ChP and AgP was made. Although our 
work revealed not significant results it is not excluded 
that ChP and AgP differ in the formation of ACPA. 
Thirdly, the detection limits for ACPA could be differ-
ent between the various papers. For instance, the cut-off 
for detection of anti-CCP was 4.5 UE/ml in a Japanese 
study [20] in comparison to our study with a cut off of 
5.0 UE/ml. Fourthly, the amount of smokers may influ-
ence the number of ACPA-positive patients and controls 
[6]. Lappin et al. [19] reported about a higher prevalence 
of smokers among patients with periodontitis (41  %) 
and controls (44 %) compared to Pablo et  al. [5] (24 vs. 
22 %) and our study (GAgP 33 %, GChP 27.1 %, controls 
21.3 %). However, regarding our data we could not show 
an association between smoking status and anti-CEP-1 
antibodies. Fifthly, studies revealed that the generation 
of autoantibodies is influenced by the individual expres-
sion of certain RA-associated HLA-DRB1 molecules 
[13, 42]. Although we were unable to show associations 
of HLA-DRB1*01 and HLA-DRB1*04 to both anti-CCP 
and anti-CEP-1 levels, the HLA genetic background 
may be important to initiate an autoimmune reaction 
Fig. 3 a, b Boxplots of anti‑CEP‑1 plasma levels in dependence on expression of HLA‑DQB1*06 (a) and HLA‑DRB1*13; DRB3*; DQB1*06 (b). The 
medians of anti‑CEP‑1 plasma levels between the groups were compared using Mann–Whitney U test.
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to citrullinated peptides. Since the distribution of HLA 
alleles depends on the ethnic origin, differences in ACPA 
levels in various groups are probable.
The revealed associations of HLA-DQB1*06 and 
HLA-DRB1*13;DRB3*;DQB1*06 to anti-CEP-1 have to 
be interpreted with caution due to the small number of 
anti-CEP-1 positive individuals in the study. Moreover, a 
simultaneous association of these HLA alleles to GAgP 
could not be observed. Whether these HLA alleles are 
actually important for the binding and presentation of 
citrullinated alpha-enolase needs to be investigated in 
HLA binding assays.
In summary we did not find significant associations 
to peripheral anti-CCP and anti-CEP-1 antibodies in 
both patients with GAgP and GChP in comparison to 
non-periodontitis controls. Patients who were infected 
with P. gingivalis had only slightly elevated anti-CEP-1 
levels. None of the other investigated bacteria were sig-
nificantly associated with circulating ACPA. Carriers of 
HLA-DQB1*06 or HLA-DRB1*13;DRB3*;DQB1*06 had 
slightly higher anti-CEP-1 levels than study participants 
who were not carrier of these HLA alleles. An asso-
ciation of ACPA to RA linked HLA-alleles could not be 
confirmed.
Conclusion
Both, GAgP and GChP and an infection with P. gingivalis, 
A. actinomycetemcomitans, P. intermedia, T. forsythia, 
and T. denticola were not significantly associated to 
peripheral anti-CCP and anti-CEP-1 antibodies. Moreo-
ver, a significant association of HLA to ACPA could not 
be detected. The underlying biological mechanisms for 
the relationship between periodontitis and RA need to be 
investigated in further studies.
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